MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a mitochondrial-derived peptide consisting of 16 amino acids. It is encoded within the mitochondrial genome and functions as a signaling molecule that regulates metabolic homeostasis.
MOTS-c is unique among peptides because it originates from mitochondrial DNA rather than nuclear DNA. It has been shown to regulate insulin sensitivity, glucose metabolism, and exercise capacity in preclinical studies.
MOTS-c is not FDA-approved for medical use. Research is primarily preclinical, with growing interest in its potential for metabolic disease and aging. It is available through compounding pharmacies for off-label use.
Most evidence comes from animal studies; human clinical data is limited.
MOTS-c acts through several metabolic pathways:
MOTS-c essentially mimics some of the metabolic benefits of exercise at the cellular level.
The landmark study identifying MOTS-c as a mitochondrial-derived peptide that regulates insulin sensitivity and metabolic homeostasis.
Research demonstrating that MOTS-c enhances exercise capacity and skeletal muscle adaptation through AMPK activation.
Study examining the role of MOTS-c in aging, showing declining levels with age and potential as a longevity-promoting peptide.
If you're using a browser with advanced ad blocking security measures, the above study links may not work. You can copy the link and paste it into a new window.
Disclaimer: The information on this page was generated with the assistance of artificial intelligence and compiled from publicly available sources. While efforts are made to ensure accuracy, information may be incomplete, outdated, or incorrect and should not be relied upon as medical advice.
R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded drugs have not been approved by the FDA; have not been reviewed by the FDA for safety, efficacy, or quality; and have not been demonstrated to the FDA to be safe or effective for their intended use. The processes by which the compounded drugs are manufactured have not been reviewed by the FDA. FDA approved products containing semaglutide and tirzepatide are available.